Sydnexis

📍 Del Mar, United States🗓 Founded 2014👥 21 employees💰 Last funded Apr 2025
Pharmaceutical Manufacturing🌐 sydnexis.com
Website LinkedIn
Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious ophthalmic co- morbidities. The greater myopia severity, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded with the goal of developing a proprietary, stable, low-dose atropine eyedrop to treat myopia progression in children and minimize the risk of ocular co-morbidities. At Sydnexis, we have focused on developing a best-in-class low-dose atropine formulation to address the juvenile-onset myopia pandemic.
3
Total investors
0
Early stage
0
Mid stage
2
Late stage
2014
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2020–2025 · investors recorded per year
202012023120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Sydnexis?
Sydnexis has 3 investors on record on gritt.io and 2 late-stage investors.
When did Sydnexis last raise funding?
The most recent investment in Sydnexis recorded on gritt.io was in April 2025.
When was Sydnexis founded?
Sydnexis was founded in 2014.
What industry is Sydnexis in?
Sydnexis operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Sydnexis based?
Sydnexis is headquartered in Del Mar, United States.